Clearpoint Neuro (CLPT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for May 20, 2026, to be held virtually at 10:00 AM Pacific Time.
Stockholders can vote electronically or request paper copies of proxy materials.
Proxy materials include the 2026 Proxy Statement, 2025 Annual Report, and Proxy Card.
Voting matters and shareholder proposals
Election of seven directors to serve until the 2027 Annual Meeting.
Ratification of Cherry Bekaert LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory (non-binding) vote to approve executive compensation.
Approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan.
Consideration of other matters that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Seven director nominees are presented for election for a one-year term ending at the 2027 Annual Meeting.
Latest events from Clearpoint Neuro
- 2024 revenue rose 31% to $31.4M; 2025 guidance targets up to 31% growth and global expansion.CLPT
Q4 20248 Jul 2026 - Q2 revenue up 32% to $7.9M, gross margin at 63%, and 2024 guidance raised to $33M.CLPT
Q2 20248 Jul 2026 - Q3 revenue up 9% to $8.9M, gross margin at 63%, IRRAS acquisition to drive future growth.CLPT
Q3 20258 Jul 2026 - Q1 2026 revenue up 43% to $12.1M, margin at 64%, but net loss widened on higher expenses.CLPT
Q1 202613 May 2026 - Pursuing $500m revenue with a global neuro platform and 60+ pharma partners in cell and gene therapy.CLPT
Investor presentation13 May 2026 - Annual meeting to vote on directors, auditor, executive pay, and expanded equity plan.CLPT
Proxy filing10 Apr 2026 - Four-pillar strategy drives neuro innovation, aiming for $200m+ revenue and global leadership.CLPT
Corporate presentation17 Mar 2026 - Record 2025 revenue and IRRAS acquisition drive double-digit growth outlook for 2026.CLPT
Q4 202517 Mar 2026 - Q3 revenue up 41% to $8.1M, gross margin 60%, debt repaid, 2024 guidance $30–33M.CLPT
Q3 202415 Jan 2026